The Bayer Of Bad News

Germany’s Bayer was the bearer of bad news for investors today, with shares experiencing their largest one-day decline in over three years. 📉

The pharma and biotech company aborted a large late-stage trial testing a new anti-clotting drug due to a lack of efficacy. While failures are common in this field, this was the company’s most promising development project. Its statement says that the experimental anticoagulant asundexian was shown to be inferior to Bristol-Myers Squibb and Pfizer’s established treatments. ❌

And if that wasn’t bad enough, regulators also ordered the company to pay $1.56 billion in the latest U.S. lawsuit over its commonly-used Roundup weedkiller. A Missouri jury ordered the payout to four plaintiffs who claimed the product caused injuries, including cancer. Ultimately, it found that Bayer’s Monsanto business was liable for claims of negligence, design defects, and failing to warn plaintiffs of the potential dangers of using Roundup.

As a result of the many setbacks, new Bayer CEO Bill Anderson is reportedly weighing options to break up the company. Splitting the business into three parts: prescription drugs, consumer health products, crop chemicals and seeds, along with cost-cutting, could help revive its share price. ✂️

$BAYRY shares fell over 17% to 17-year lows as investors assess the company’s future. 🙃

More in   Earnings

View All

Speculation Heightens As Jumia Jumps

As we’ve discussed, speculation continues to spread to all corners of the market. Even those areas that have been left for dead for quite some time. Today’s example of this is Jumia Technologies, the “Amazon of Africa” that caught wildfire early in its life before the gravity of reality brought it back down to earth. 🛒

The company reported reducing its losses by over 90% in the fourth quarter as it focused on restoring order and gross merchandise value (GMV) growth. Like other struggling companies, it cut costs significantly and leveraged lower tax provisions to help drive the earnings improvement. 

Read It

Palantir Pops On Earnings

Software company Palantir Technologies is back on investors’ radars after its earnings results. 💪

The company reported adjusted earnings per share of $0.08, which matched expectations—meanwhile, revenues of $608.40 million topped expectations of $602.40 million by about 1%. 

Read It

Semis Continue To Tower Over Market

Semiconductors continue to dominate the market and thus dominate our headlines. With that said, today we’ve got a fresh stock breaking out and another setting up, so stick with us. 👇

First up is Tower Semiconductor, an Israeli chip manufacturer that reported results today. The company’s revenue fell 13% YoY to $351.7 million during the fourth quarter but topped the $350 million expected by analysts. Its earnings per share were down about 30% YoY to $0.48, but again, better than anticipated. 🔺

Read It